valproic acid has been researched along with Mental Disorders in 129 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-four new cases of childhood epilepsy were randomly assigned to either carbamazepine, phenytoin or sodium valproate, and were assessed with behavioural measures before medication and after one and six months of treatment." | 9.07 | Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. ( Berg, I; Butler, A; Ellis, M; Foster, J, 1993) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 8.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 8.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 7.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| "ALT elevations with valproic acid were significantly greater among patients with positive hepatitis C status than those with negative or unknown status." | 7.72 | The safety of valproic acid use for patients with hepatitis C infection. ( Barnes, RF; Dominitz, JA; Felker, BL; Sloan, KL, 2003) |
| "Sixty-four new cases of childhood epilepsy were randomly assigned to either carbamazepine, phenytoin or sodium valproate, and were assessed with behavioural measures before medication and after one and six months of treatment." | 5.07 | Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. ( Berg, I; Butler, A; Ellis, M; Foster, J, 1993) |
| "Valproic acid (VPA) use during pregnancy increases fetal risk of major congenital malformations and cognitive impairment." | 4.93 | Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review. ( Gotlib, D; Kurlander, J; Muzik, M; Perelstein, E; Riba, M; Zivin, K, 2016) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 4.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 4.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| " Reversible dystonia may occasionally be precipitated by phenytoin or carbamazepine; asterixis by phenytoin, barbiturates or carbamazepine; and, more commonly, tremor by valproate." | 4.77 | Adverse neuropsychiatric effects of anticonvulsant drugs. ( Reynolds, EH; Trimble, MR, 1985) |
| " The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)." | 4.12 | Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 3.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| " Dosing was individualized according to the response of target symptoms and side effects." | 3.78 | An open trial of valproate for agitation in geriatric neuropsychiatric disorders. ( Erb, R; Gaile, S; Porsteinsson, AP; Tariot, PN, 1997) |
| "Valproic acid is increasingly used in the treatment of epilepsy, and also prescribed for bipolar affective disorders, schizoaffective disorders, schizophrenia and migraine prophylaxis." | 3.72 | Valproic acid intoxication: sense and non-sense of haemodialysis. ( Boerma, EC; Broekroelofs, J; Egbers, PH; Meek, MF; van der Voort, PH; Yska, JP, 2004) |
| "ALT elevations with valproic acid were significantly greater among patients with positive hepatitis C status than those with negative or unknown status." | 3.72 | The safety of valproic acid use for patients with hepatitis C infection. ( Barnes, RF; Dominitz, JA; Felker, BL; Sloan, KL, 2003) |
| " The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER." | 2.82 | Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. ( Ariyawansa, J; Berwaerts, J; Coppola, D; De Meulder, M; Remmerie, B, 2016) |
| "Predictors of response to divalproex treatment for conduct disorder were identified, despite the small sample size in this study." | 2.71 | Baseline predictors of response to divalproex in conduct disorder. ( Chang, K; Khanzode, L; Saxena, K; Silverman, MA; Steiner, H, 2005) |
| " Side effects were assessed using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale." | 2.71 | Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. ( Cunanan, C; Horne, RL, 2003) |
| "The authors discuss adverse events which are often missed but clinicians should pay attention to in order to preserve patients'quality of life(QOL)." | 2.50 | [Adverse events of psychotropic drugs]. ( Kikuchi, T; Watanabe, K, 2014) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "It has been used in other psychiatric disorders, including schizophrenia and borderline personality disorder, but data are insufficient to recommend this." | 2.45 | A review of valproate in psychiatric practice. ( Ashfaq, M; Das, A; Haddad, PM; Wieck, A, 2009) |
| "Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications." | 2.43 | [Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006) |
| "Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children." | 2.43 | Recognizing and managing bipolar disorder in children. ( Wozniak, J, 2005) |
| "There are clear connections between migraine and psychiatric disorders and the attending physician should have them in mind." | 2.42 | [Migraine and psychiatric disorders]. ( Fasmer, OB; Oedegaard, KJ, 2004) |
| "Valproic acid was used as an organic solvent in research laboratories for eight decades, until the fortuitous observation of action against pentylenetetrazol-induced convulsions in rodents." | 2.42 | The history of valproate in clinical neuroscience. ( Henry, TR, 2003) |
| "Mood disorders have traditionally been conceptualized as neurochemical disorders, but there is now evidence from a variety of sources demonstrating regional reductions in central nervous system (CNS) volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas." | 2.42 | The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. ( Du, J; Gray, NA; Manji, HK; Moore, GJ; Zhou, R, 2003) |
| "Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS." | 2.39 | Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. ( Moore, DP, 1996) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "This study included 126 patients with psychiatric disorders on mono- or co-therapy with CLZ." | 1.91 | Association of clozapine and norclozapine levels with patient and therapy characteristics-focus on interaction with valproic acid. ( Jovanović, M; Lukić, V; Miljković, B; Milovanović, S; Panić, B; Vučićević, K, 2023) |
| "Individuals with serious mental illness are at increased risk of severe COVID-19 infection." | 1.72 | Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System. ( Capichioni, G; Clelland, J; Finnerty, M; Goff, DC; Kammer, J; Leckman-Westin, E; Lindenmayer, JP; Nemani, K; Olfson, M; Silverman, DJ; Smith, TE; Williams, SZ, 2022) |
| " Patient characteristics, VPA use, and adverse effects (thrombocytopenia, hyperammonemia, and hepatotoxicity) were recorded." | 1.56 | Safety range of free valproic acid serum concentration in adult patients. ( Huang, SY; Kuo, CH; Tseng, YJ; Wang, CY; Wang, KC; Wu, CC, 2020) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "The rate of severe PD-related hair loss was very low in the present survey." | 1.48 | Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries. ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018) |
| "Epilepsy was the most frequent diagnosis (46%) recorded within the year prior to the first AED dispensing." | 1.48 | Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses. ( Karlsson Lind, L; von Euler, M; Wettermark, B; Wide, K, 2018) |
| "Coexisting psychiatric disorders (PDs) were found in 33." | 1.40 | Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy. ( Bana, AK; Jayalakshmi, S; Mohandas, S; Sailaja, S; Somayajula, S; Vooturi, S, 2014) |
| "Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential." | 1.39 | Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. ( Christensen, J; Grønborg, TK; Parner, ET; Pedersen, LH; Schendel, D; Sørensen, MJ; Vestergaard, M, 2013) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "Valproic acid (VPA) has been used for decades in the treatment of epilepsy and psychiatric disorders, and the long-term use of VPA is regularly accompanied by hematological toxicity, including neutropenia." | 1.38 | Valproic acid treatment is associated with altered leukocyte subset development. ( Bartels, M; Bierings, MB; Coffer, PJ; den Breeijen, HJ; Egberts, TC; van Solinge, WW, 2012) |
| "As carnitine deficiency is a potentially treatable condition further studies are warranted." | 1.37 | Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients. ( Abramson, RK; Cuturic, M; Hall, AV; Hardin, JW; Moran, RR, 2011) |
| " The patients' characteristics and pharmacokinetic parameters were compared between the 2 dosage groups using independent t test or χ² test where appropriate." | 1.37 | The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ( Chamchitchun, S; Panomvana, D; Silpakit, O; Sriboonruang, T, 2011) |
| "Cyproterone acetate was used in a small number of patients at each of the three units." | 1.37 | Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units. ( Lemon, V; Restifo, S; Waters, F, 2011) |
| " Our findings also suggest that ethnic traits may affect carnitine bioavailability as well as cognitive outcomes in this clinical context." | 1.36 | Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. ( Abramson, RK; Cuturic, M; Hardin, JW; Moran, RR, 2010) |
| "Anticonvulsant use for seizure control was proportionally greater for those younger than five years." | 1.33 | Anticonvulsant treatment for psychiatric and seizure indications among youths. ( Gardner, JF; Ryu, J; Safer, DJ; Soeken, K; Zito, JM, 2006) |
| "We followed 23 patients with pediatric migraine, ranging in age from 7 to 17 years, who were treated with preventive divalproex sodium for migraine prophylaxis." | 1.31 | Pediatric migraine prophylaxis with divalproex. ( Drake, ME; Greenberg, G; Pakalnis, A; Paolichi, J, 2001) |
| " Patients treated with divalproex sodium compared with patients treated with valproic acid were less likely to experience gastrointestinal side effects and to have discontinued their medication because of an adverse event." | 1.30 | The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. ( Madrid, AR; McDonald, J; Narendran, R; Sederer, M; Tohen, M; Tomassini, EC; Zarate, CA, 1999) |
| "Diazepam, 7 mg, was given intravenously." | 1.26 | [Stupor due to sodium valproate. Immediate arousal after intravenous diazepam (author's transl)]. ( Bonardi, JM; Juif, J; Marescaux, C; Micheletti, G; Rumbach, L; Warter, JM, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (12.40) | 18.7374 |
| 1990's | 22 (17.05) | 18.2507 |
| 2000's | 43 (33.33) | 29.6817 |
| 2010's | 36 (27.91) | 24.3611 |
| 2020's | 12 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Fernström, J | 1 |
| Ohlsson, L | 1 |
| Asp, M | 1 |
| Lavant, E | 1 |
| Holck, A | 1 |
| Grudet, C | 1 |
| Westrin, Å | 1 |
| Lindqvist, D | 1 |
| Andrade, C | 1 |
| Jyothi, SA | 1 |
| Renitha, T | 1 |
| Anuroopa, KP | 1 |
| Dona, B | 1 |
| Basila, T | 1 |
| Nimmy, G | 1 |
| Nemani, K | 1 |
| Williams, SZ | 1 |
| Olfson, M | 1 |
| Leckman-Westin, E | 1 |
| Finnerty, M | 1 |
| Kammer, J | 1 |
| Smith, TE | 1 |
| Silverman, DJ | 1 |
| Lindenmayer, JP | 2 |
| Capichioni, G | 1 |
| Clelland, J | 1 |
| Goff, DC | 1 |
| Hefner, G | 1 |
| Wolff, J | 1 |
| Toto, S | 2 |
| Reißner, P | 1 |
| Klimke, A | 1 |
| Semman, MF | 1 |
| Dadi, FG | 1 |
| Ijigu, GM | 1 |
| Moges, BT | 1 |
| Tesfaye, BT | 1 |
| Panić, B | 1 |
| Jovanović, M | 1 |
| Lukić, V | 1 |
| Vučićević, K | 1 |
| Miljković, B | 1 |
| Milovanović, S | 1 |
| Ľupták, M | 1 |
| Hroudová, J | 1 |
| Baldwin, DS | 1 |
| Amaro, HJF | 1 |
| Esposito, M | 1 |
| Giunta, A | 1 |
| Del Duca, E | 1 |
| Manfreda, V | 1 |
| Troisi, A | 1 |
| Bianchi, L | 1 |
| Fargnoli, MC | 1 |
| Puig-Molto, M | 1 |
| Pol-Yanguas, E | 1 |
| Segarra, L | 1 |
| Lumbreras, B | 1 |
| Muñoz-Pichuante, D | 1 |
| Villa-Zapata, L | 1 |
| Lolas, R | 1 |
| Andrade, G | 1 |
| Simões do Couto, F | 1 |
| Câmara-Pestana, L | 1 |
| Tseng, YJ | 1 |
| Huang, SY | 1 |
| Kuo, CH | 1 |
| Wang, CY | 1 |
| Wang, KC | 1 |
| Wu, CC | 1 |
| Jamal, I | 1 |
| Kumar, V | 1 |
| Vatsa, N | 1 |
| Shekhar, S | 1 |
| Singh, BK | 1 |
| Sharma, A | 1 |
| Jana, NR | 1 |
| Yamaguchi, H | 1 |
| Hara, Y | 1 |
| Ago, Y | 1 |
| Takano, E | 1 |
| Hasebe, S | 1 |
| Nakazawa, T | 1 |
| Hashimoto, H | 1 |
| Matsuda, T | 1 |
| Takuma, K | 1 |
| Gotlib, D | 2 |
| Ramaswamy, R | 1 |
| Kurlander, JE | 1 |
| DeRiggi, A | 1 |
| Riba, M | 2 |
| Karlsson Lind, L | 1 |
| Wide, K | 1 |
| Wettermark, B | 1 |
| von Euler, M | 1 |
| Druschky, K | 1 |
| Bleich, S | 1 |
| Grohmann, R | 1 |
| Burda, K | 1 |
| Frieling, H | 1 |
| Hillemacher, T | 1 |
| Neyazi, A | 1 |
| Stübner, S | 1 |
| Gearhart, AM | 1 |
| Guardiola, JJ | 1 |
| El-Kersh, K | 1 |
| Toral, D | 1 |
| Belzeaux, R | 1 |
| Dumas, R | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| Uys, H | 1 |
| Christensen, J | 1 |
| Grønborg, TK | 1 |
| Sørensen, MJ | 1 |
| Schendel, D | 1 |
| Parner, ET | 1 |
| Pedersen, LH | 1 |
| Vestergaard, M | 1 |
| Allen, MB | 1 |
| Baker, JC | 1 |
| Nuernberger, JE | 1 |
| Vargo, KK | 1 |
| Monji, A | 1 |
| Motomura, K | 1 |
| Mizoguchi, Y | 1 |
| Ohara, T | 1 |
| Baba, S | 1 |
| Yoshiura, T | 1 |
| Kanba, S | 1 |
| Diaz, FJ | 1 |
| Eap, CB | 1 |
| Ansermot, N | 1 |
| Crettol, S | 1 |
| Spina, E | 1 |
| de Leon, J | 1 |
| Jayalakshmi, S | 1 |
| Vooturi, S | 1 |
| Bana, AK | 1 |
| Sailaja, S | 1 |
| Somayajula, S | 1 |
| Mohandas, S | 1 |
| Watanabe, K | 1 |
| Kikuchi, T | 1 |
| Smith, EG | 2 |
| Austin, KL | 2 |
| Kim, HM | 2 |
| Miller, DR | 2 |
| Eisen, SV | 2 |
| Christiansen, CL | 1 |
| Kilbourne, AM | 2 |
| Sauer, BC | 2 |
| McCarthy, JF | 1 |
| Valenstein, M | 2 |
| Zivin, K | 2 |
| Hannemann, C | 1 |
| Amitai, M | 1 |
| Sachs, E | 1 |
| Zivony, A | 1 |
| Remez, R | 1 |
| Ben Baruch, R | 1 |
| Amit, BH | 1 |
| Kronenberg, S | 1 |
| Apter, A | 1 |
| Shoval, G | 1 |
| Weizman, A | 1 |
| Zalsman, G | 1 |
| Remmerie, B | 1 |
| Ariyawansa, J | 1 |
| De Meulder, M | 1 |
| Coppola, D | 1 |
| Berwaerts, J | 1 |
| Chowdhury, A | 1 |
| Brodie, MJ | 1 |
| Thomas, KL | 1 |
| La, AQ | 1 |
| Punia, S | 1 |
| Doroudgar, S | 1 |
| Perry, PJ | 1 |
| Perelstein, E | 1 |
| Kurlander, J | 1 |
| Muzik, M | 1 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Shepard, R | 1 |
| Heslin, K | 1 |
| Coutellier, L | 1 |
| Dealberto, MJ | 1 |
| Sarazin, FF | 1 |
| Haddad, PM | 1 |
| Das, A | 1 |
| Ashfaq, M | 1 |
| Wieck, A | 1 |
| Zheleznova, EV | 1 |
| Kalinin, VV | 1 |
| Zemlyanaya, AA | 1 |
| Sokolova, LV | 1 |
| Medvedev, IL | 1 |
| Cuturic, M | 2 |
| Abramson, RK | 2 |
| Moran, RR | 2 |
| Hardin, JW | 2 |
| Khoo, CL | 1 |
| Naik, S | 1 |
| Lua, R | 1 |
| Chai, SB | 1 |
| Liew, A | 1 |
| Sim, K | 1 |
| Vasudev, K | 1 |
| Keown, P | 1 |
| Gibb, I | 1 |
| McAllister-Williams, RH | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Hall, AV | 1 |
| Restifo, S | 1 |
| Lemon, V | 1 |
| Waters, F | 1 |
| Sriboonruang, T | 1 |
| Panomvana, D | 1 |
| Chamchitchun, S | 1 |
| Silpakit, O | 1 |
| Ohadi, M | 1 |
| Mirabzadeh, A | 1 |
| Esmaeilzadeh-Gharehdaghi, E | 1 |
| Rezazadeh, M | 1 |
| Hosseinkhanni, S | 1 |
| Oladnabi, M | 1 |
| Firouzabadi, SG | 1 |
| Darvish, H | 1 |
| Bartels, M | 1 |
| van Solinge, WW | 1 |
| den Breeijen, HJ | 1 |
| Bierings, MB | 1 |
| Coffer, PJ | 1 |
| Egberts, TC | 1 |
| Cheng, M | 1 |
| Tang, X | 1 |
| Wen, S | 1 |
| Yue, J | 1 |
| Wang, H | 1 |
| Felker, BL | 1 |
| Sloan, KL | 1 |
| Dominitz, JA | 1 |
| Barnes, RF | 1 |
| Horne, RL | 1 |
| Cunanan, C | 1 |
| Gray, NA | 1 |
| Zhou, R | 1 |
| Du, J | 1 |
| Moore, GJ | 1 |
| Manji, HK | 1 |
| Chang, KD | 1 |
| Dienes, K | 1 |
| Blasey, C | 1 |
| Adleman, N | 1 |
| Ketter, T | 1 |
| Steiner, H | 4 |
| Henry, TR | 1 |
| Tariot, PN | 2 |
| Le Fauve, CE | 1 |
| Litten, RZ | 1 |
| Randall, CL | 1 |
| Moak, DH | 1 |
| Salloum, IM | 1 |
| Green, AI | 1 |
| Cramer, JA | 1 |
| Sernyak, M | 1 |
| Hirsch, LJ | 1 |
| Weintraub, D | 1 |
| Du, Y | 1 |
| Buchsbaum, R | 1 |
| Spencer, HT | 1 |
| Hager, M | 1 |
| Straka, T | 1 |
| Bazil, CW | 1 |
| Adams, DJ | 1 |
| Resor, SR | 1 |
| Morrell, MJ | 1 |
| Fasmer, OB | 1 |
| Oedegaard, KJ | 1 |
| Dravet, C | 1 |
| Bureau, M | 1 |
| Meek, MF | 1 |
| Broekroelofs, J | 1 |
| Yska, JP | 1 |
| Egbers, PH | 1 |
| Boerma, EC | 1 |
| van der Voort, PH | 1 |
| Minirth, FB | 1 |
| Neal, V | 1 |
| Wassef, AA | 1 |
| Winkler, DE | 1 |
| Roache, AL | 1 |
| Abobo, VB | 1 |
| Lopez, LM | 1 |
| Averill, JP | 1 |
| Mian, AI | 1 |
| Overall, JE | 1 |
| Wozniak, J | 2 |
| Rana, M | 1 |
| Khanzode, L | 2 |
| Karnik, N | 1 |
| Saxena, K | 2 |
| Chang, K | 2 |
| Moreno, FA | 1 |
| Macey, H | 1 |
| Schreiber, B | 1 |
| Seymour, HM | 1 |
| Glendenning, P | 1 |
| Peterson, GM | 1 |
| Naunton, M | 1 |
| Silverman, MA | 1 |
| de Araujo Filho, GM | 1 |
| Pascalicchio, TF | 1 |
| Lin, K | 1 |
| Sousa, PS | 1 |
| Yacubian, EM | 1 |
| Surve, TY | 1 |
| Mittal, G | 1 |
| Khadse, SS | 1 |
| Khanna, SA | 1 |
| Schmitz, B | 2 |
| Krämer, G | 1 |
| Helmstädter, C | 1 |
| Jokeit, H | 1 |
| Koch, S | 1 |
| Luef, G | 1 |
| Schaefer, C | 1 |
| Zito, JM | 1 |
| Safer, DJ | 1 |
| Gardner, JF | 1 |
| Soeken, K | 1 |
| Ryu, J | 1 |
| Ben-Menachem, E | 1 |
| Tomson, T | 1 |
| Vajda, F | 1 |
| Viinikainen, K | 1 |
| Eriksson, K | 1 |
| Mönkkönen, A | 1 |
| Aikiä, M | 1 |
| Nieminen, P | 1 |
| Heinonen, S | 1 |
| Kälviäinen, R | 1 |
| Porsteinsson, AP | 2 |
| Bidzan, L | 1 |
| Plattner, B | 1 |
| Pahs, G | 1 |
| Kindler, J | 1 |
| Williams, RP | 1 |
| Hall, RE | 1 |
| Mayer, H | 1 |
| Feucht, M | 1 |
| Drotar, D | 1 |
| Greenley, RN | 1 |
| Demeter, CA | 1 |
| McNamara, NK | 1 |
| Stansbrey, RJ | 1 |
| Calabrese, JR | 1 |
| Stange, J | 1 |
| Vijay, P | 1 |
| Findling, RL | 1 |
| Qalbani, M | 1 |
| De León, OA | 1 |
| Greiner, C | 1 |
| Wittmann, M | 1 |
| Haen, E | 1 |
| Ances, BM | 1 |
| Letendre, SL | 1 |
| Alexander, T | 1 |
| Ellis, RJ | 1 |
| Tollefson, G | 1 |
| Chapman, A | 1 |
| Keane, PE | 1 |
| Meldrum, BS | 1 |
| Simiand, J | 1 |
| Vernieres, JC | 1 |
| Kugoh, T | 1 |
| Hosokawa, K | 1 |
| Meldrum, B | 1 |
| Reynolds, EH | 2 |
| Schmidt, D | 1 |
| Marescaux, C | 1 |
| Bonardi, JM | 1 |
| Rumbach, L | 1 |
| Warter, JM | 1 |
| Juif, J | 1 |
| Micheletti, G | 1 |
| Wilcox, J | 1 |
| Janicak, PG | 1 |
| Berg, I | 1 |
| Butler, A | 1 |
| Ellis, M | 1 |
| Foster, J | 1 |
| Puryear, LJ | 1 |
| Kunik, ME | 1 |
| Workman, R | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Donovan, SJ | 1 |
| Susser, ES | 1 |
| Nunes, EV | 1 |
| Stewart, JW | 1 |
| Quitkin, FM | 1 |
| Klein, DF | 1 |
| Zarate, CA | 2 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 2 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 2 |
| Erb, R | 1 |
| Gaile, S | 1 |
| Narayan, M | 1 |
| Nelson, JC | 1 |
| Jacob, PC | 1 |
| Chand, RP | 1 |
| Moore, DP | 1 |
| Sherr, JD | 1 |
| Kelly, DL | 1 |
| Biederman, J | 1 |
| Mick, E | 1 |
| Bostic, JQ | 1 |
| Prince, J | 1 |
| Daly, J | 1 |
| Wilens, TE | 1 |
| Spencer, T | 1 |
| Garcia-Jetton, J | 1 |
| Russell, R | 1 |
| Faraone, SV | 1 |
| Niedermier, JA | 1 |
| Nasrallah, HA | 1 |
| Austin, MP | 1 |
| Mitchell, PB | 1 |
| Bowden, CL | 1 |
| Narendran, R | 1 |
| Tomassini, EC | 1 |
| Sederer, M | 1 |
| Madrid, AR | 1 |
| Panikkar, GP | 1 |
| Gilman, SM | 1 |
| Kotsaftis, A | 1 |
| Soares, JC | 1 |
| Gershon, S | 1 |
| Wagner, PG | 1 |
| Welton, SR | 1 |
| Hammond, CM | 1 |
| Trannel, TJ | 1 |
| Ahmed, I | 1 |
| Goebert, D | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Pakalnis, A | 1 |
| Greenberg, G | 1 |
| Drake, ME | 1 |
| Paolichi, J | 1 |
| Lott, RS | 1 |
| Helmboldt, KM | 1 |
| Madaras-Kelly, KJ | 1 |
| Hellings, JA | 1 |
| Hossain, S | 1 |
| Martin, JK | 1 |
| Baratang, RR | 1 |
| Campanini, T | 1 |
| Catalano, A | 1 |
| De Risio, C | 1 |
| Forino, V | 1 |
| Cocchi, R | 2 |
| Fusari, A | 2 |
| Lorini, G | 2 |
| Roccia, L | 1 |
| Favuto, F | 1 |
| Semadeni, GW | 1 |
| Fenwick, PB | 1 |
| Keck, PE | 3 |
| McElroy, SL | 3 |
| Friedman, LM | 1 |
| Lum, M | 1 |
| Fontaine, R | 1 |
| Elie, R | 1 |
| Ontiveros, A | 1 |
| Pope, HG | 2 |
| Hudson, JI | 1 |
| Trimble, MR | 1 |
| van Sweden, B | 1 |
| van Moffaert, M | 1 |
| Vaĭntrub, MIa | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder[NCT00203528] | Phase 4 | 30 participants | Interventional | 2004-01-31 | Completed | ||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
37 reviews available for valproic acid and Mental Disorders
| Article | Year |
|---|---|
Important role of mitochondria and the effect of mood stabilizers on mitochondrial function.
Topics: Calcium; Energy Metabolism; Humans; Lithium; Mental Disorders; Mitochondria; Psychotropic Drugs; Rea | 2019 |
Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?
Topics: Anticonvulsants; Female; Humans; Mental Disorders; Prescription Drugs; Valproic Acid; Women | 2020 |
[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].
Topics: Antiviral Agents; Benzodiazepines; Betacoronavirus; Bipolar Disorder; Body Temperature Regulation; B | 2020 |
Valproic Acid in Women and Girls of Childbearing Age.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Antimanic Agents; Europe; Female; H | 2017 |
[Adverse events of psychotropic drugs].
Topics: Animals; Anticonvulsants; Humans; Japan; Lithium; Mental Disorders; Psychotropic Drugs; Quality of L | 2014 |
Guideline adherence for mentally ill reproductive-aged women on treatment with valproic acid: a retrospective chart review.
Topics: Abnormalities, Drug-Induced; Contraception Behavior; Female; Folic Acid; Guideline Adherence; Humans | 2016 |
A review of valproate in psychiatric practice.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2009 |
Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature.
Topics: Adult; Antimanic Agents; Female; Humans; Hyperammonemia; Mental Disorders; Valproic Acid | 2010 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
Topics: Anticonvulsants; Apoptosis; Atrophy; Brain; Central Nervous System Diseases; Gene Expression; Genes, | 2003 |
The history of valproate in clinical neuroscience.
Topics: Anticonvulsants; Antimanic Agents; Clinical Trials as Topic; History, 20th Century; Humans; Mental D | 2003 |
Valproate use in neuropsychiatric disorders in the elderly.
Topics: Aged; Animals; Anticonvulsants; Clinical Trials as Topic; Humans; Mental Disorders; Nervous System D | 2003 |
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Eruptions; Drug Interactions; Drug Therapy, | 2004 |
[Migraine and psychiatric disorders].
Topics: Antidepressive Agents; Antimanic Agents; Anxiety Disorders; Comorbidity; Humans; Mental Disorders; M | 2004 |
Benign myoclonic epilepsy in infancy.
Topics: Age of Onset; Anticonvulsants; Child, Preschool; Electroencephalography; Epilepsies, Myoclonic; Fema | 2005 |
Recognizing and managing bipolar disorder in children.
Topics: Adolescent; Age Factors; Amphetamine; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disor | 2005 |
Divalproex sodium in the treatment of pediatric psychiatric disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autistic Diso | 2005 |
Valproate: a simple chemical with so much to offer.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Epilepsy; Female; History, 20th Century; Hu | 2005 |
[Neuropsychological outcome following intrauterine exposure to valproate].
Topics: Female; Germany; Humans; Intellectual Disability; Mental Disorders; Practice Guidelines as Topic; Pr | 2006 |
Role of valproate across the ages. Treatment of epilepsy in adults.
Topics: Adult; Age Factors; Anticonvulsants; Child; Developmental Disabilities; Epilepsy; Female; Fertility; | 2006 |
Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Neuroprotecti | 2006 |
[Anticonvulsants treatment of psychiatric disorder in elderly patients].
Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental | 2006 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Human | 2008 |
Mechanism of anticonvulsant action of valproate.
Topics: Animals; Aspartic Acid; Cats; Central Nervous System; Epilepsy; gamma-Aminobutyric Acid; Half-Life; | 1982 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Mental effects of antiepileptic medication: a review.
Topics: Adolescent; Adult; Anticonvulsants; Attention; Barbiturates; Brain Chemistry; Carbamazepine; Child; | 1983 |
The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics.
Topics: Anticonvulsants; Antipsychotic Agents; Carbamazepine; Delayed-Action Preparations; Drug Interactions | 1993 |
An open trial of valproate for agitation in geriatric neuropsychiatric disorders.
Topics: Aged; Alzheimer Disease; Female; GABA Agents; Humans; Male; Mental Disorders; Valproic Acid | 1997 |
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review.
Topics: Adult; Autoimmune Diseases; Chorea; Comorbidity; Haloperidol; Humans; Mental Disorders; Obsessive-Co | 1996 |
Use of psychotropic medications in breast-feeding women: acute and prophylactic treatment.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Breast Feeding; Carbamazepine; Depression, Postpa | 1998 |
Use of sodium valproate in violent and aggressive behaviors: a critical review.
Topics: Adolescent; Adult; Aged; Aggression; Anticonvulsants; Antimanic Agents; Child; Clinical Trials as To | 2000 |
The psychopharmacologic specificity of the lithium ion: origins and trajectory.
Topics: Anticonvulsants; Australia; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; History, 20t | 2000 |
Psychopathology, GABA, and the Rubinstein-Taybi syndrome: a review and case study.
Topics: Adult; Chromosome Deletion; Chromosomes, Human, Pair 16; Female; GABA Agonists; Humans; Mental Disor | 2002 |
Antiepileptic drugs and their psychotropic effects.
Topics: Affect; Anticonvulsants; Brain; Carbamazepine; Clonazepam; Epilepsy; Humans; Mental Disorders; Psych | 1992 |
Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes.
Topics: Carbamazepine; Humans; Mental Disorders; Panic Disorder; Stress Disorders, Post-Traumatic; Substance | 1992 |
Valproate in psychiatric disorders: literature review and clinical guidelines.
Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic | 1989 |
Adverse neuropsychiatric effects of anticonvulsant drugs.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Biogenic Amines; Carba | 1985 |
14 trials available for valproic acid and Mental Disorders
| Article | Year |
|---|---|
Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Delayed-Action Preparations; Drug Interactions; Drug | 2016 |
Monotherapy of epilepsy in women: psychiatric and neuroendocrine aspects.
Topics: Adult; Anticonvulsants; Barbiturates; Carbamazepine; Epilepsies, Partial; Epilepsy, Generalized; Est | 2010 |
Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Area Under Curve; Chemistry, Pharmaceu | 2003 |
Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms.
Topics: Adolescent; Affective Symptoms; Anticonvulsants; Bipolar Disorder; Child; Child of Impaired Parents; | 2003 |
Assessment of patient preference and side effects in patients switched from divalproex sodium delayed release to divalproex sodium extended release.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Child; Delayed-Action Preparations; Female; Humans; Male; | 2005 |
Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
Topics: Adult; Analysis of Variance; Anticonvulsants; Delayed-Action Preparations; Drugs, Generic; Female; H | 2005 |
Baseline predictors of response to divalproex in conduct disorder.
Topics: Adaptation, Psychological; Adolescent; Anticonvulsants; Comorbidity; Conduct Disorder; Defense Mecha | 2005 |
Divalproex sodium in the treatment of aggressive behavior.
Topics: Adult; Aggression; Bipolar Disorder; Borderline Personality Disorder; Case-Control Studies; Female; | 1994 |
Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Humans; Mal | 1993 |
Divalproex treatment of disruptive adolescents: a report of 10 cases.
Topics: Adolescent; Adolescent Behavior; Aggression; Ambulatory Care; Attention Deficit Disorder with Hypera | 1997 |
An open trial of valproate for agitation in geriatric neuropsychiatric disorders.
Topics: Aged; Alzheimer Disease; Female; GABA Agents; Humans; Male; Mental Disorders; Valproic Acid | 1997 |
Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
Topics: Adult; Aged; Anticonvulsants; Dosage Forms; Female; Humans; Male; Mental Disorders; Middle Aged; Pro | 1998 |
Probable interaction of sodium divalproex with benzodiazepines.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Double-Blind Method; Drug Interactio | 1991 |
Valproate in psychiatric disorders: literature review and clinical guidelines.
Topics: Bipolar Disorder; Clinical Trials as Topic; Humans; Mental Disorders; Psychotic Disorders; Valproic | 1989 |
80 other studies available for valproic acid and Mental Disorders
| Article | Year |
|---|---|
Plasma circulating cell-free mitochondrial DNA in depressive disorders.
Topics: Biomarkers; Cell-Free Nucleic Acids; DNA, Mitochondrial; Humans; Lamotrigine; Lithium; Mental Disord | 2021 |
Use of Valproate in Women: An Audit of Prescriptions to 10,001 Psychiatry, Neurology, and Neurosurgery Outpatients.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Prescriptions; Female; Humans; India; Male; | 2021 |
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System.
Topics: Adult; Antipsychotic Agents; Cohort Studies; COVID-19; COVID-19 Testing; Female; Hospitals, Psychiat | 2022 |
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders | 2022 |
Management practice and discharge outcome of patients with psychiatric disorder admitted to psychiatry wards of selected specialized settings in Ethiopia.
Topics: Adult; Cross-Sectional Studies; Diazepam; Ethiopia; Hospitals, Psychiatric; Humans; Mental Disorders | 2023 |
Association of clozapine and norclozapine levels with patient and therapy characteristics-focus on interaction with valproic acid.
Topics: Clozapine; Humans; Mental Disorders; Retrospective Studies; Valproic Acid | 2023 |
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.
Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benz | 2020 |
Impact of the EMA/FDA alerts on the use of effective contraceptive method in women of childbearing age undergoing valproic acid treatment in a long-stay psychiatric center.
Topics: Adult; Anticonvulsants; Contraception; Drug and Narcotic Control; Drug Labeling; Epilepsy; Europe; F | 2020 |
Meropenem for management of valproic acid overdose: a case report.
Topics: Administration, Oral; Adult; Anticonvulsants; Drug Overdose; Emergency Service, Hospital; Female; Hu | 2020 |
Safety range of free valproic acid serum concentration in adult patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Dosage Forms; Dose-Response Relationship, Drug; Dru | 2020 |
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anxiety; Brain; Cell Line, Transformed; Cognition Disorders; Disease Mod | 2017 |
Environmental enrichment attenuates behavioral abnormalities in valproic acid-exposed autism model mice.
Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Brain-Derived Neurotrophic Factor; Dendritic Spi | 2017 |
Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Epilepsy | 2018 |
Severe hair loss associated with psychotropic drugs in psychiatric inpatients-Data from an observational pharmacovigilance program in German-speaking countries.
Topics: Adult; Alopecia; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Austria; Bipolar Dis | 2018 |
A 33-Year-Old Woman With Altered Mental Status and Elevated Ammonia Level.
Topics: Adult; Ammonia; Anticonvulsants; Arrhythmias, Cardiac; Drug Overdose; Female; Glasgow Coma Scale; Hu | 2018 |
Valproate delays diagnosis of anti-NMDA-receptor-encephalitis in a patient with psychiatric presentation.
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Delayed Diagnosis; Humans; Mental Disorders; Valpro | 2019 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
Topics: Adolescent; Adult; Anticonvulsants; Autistic Disorder; Child; Child Development Disorders, Pervasive | 2013 |
Precursor manic behavior in the assessment and treatment of episodic problem behavior for a woman with a dual diagnosis.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavioral Sy | 2013 |
A case of late-onset bipolar disorder with severely abnormal behavior and neuroimaging observations very similar to those of frontotemporal dementia.
Topics: Antimanic Agents; Bipolar Disorder; Frontal Lobe; Frontotemporal Dementia; Humans; Magnetic Resonanc | 2014 |
Can valproic acid be an inducer of clozapine metabolism?
Topics: Antimanic Agents; Chromatography, High Pressure Liquid; Clozapine; Drug Monitoring; Female; Humans; | 2014 |
Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Electroencephalography; Female; Humans; Longitudinal Studies; Ma | 2014 |
Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study.
Topics: Antimanic Agents; Cohort Studies; Female; Humans; Lithium Compounds; Male; Mental Disorders; Middle | 2014 |
Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Cohort Studies; Female; Humans; Lit | 2015 |
Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study.
Topics: Adolescent; Adolescent Behavior; Child; Female; Humans; Inpatients; Male; Mental Disorders; Platelet | 2015 |
Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Resistant Epilepsy; Female; Follow-Up S | 2016 |
Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
Topics: Adult; Antimanic Agents; Cognitive Dysfunction; Female; Hepatic Encephalopathy; Humans; Hyperammonem | 2016 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
The transcription factor Npas4 contributes to adolescent development of prefrontal inhibitory circuits, and to cognitive and emotional functions: Implications for neuropsychiatric disorders.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cognition; Emotions; Female; GABA Agents; gam | 2017 |
Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: a case report in the psychiatric setting.
Topics: Adult; Antimanic Agents; Female; Humans; Mental Disorders; Rett Syndrome; Valproic Acid | 2008 |
Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review.
Topics: Adult; Aged; Antimanic Agents; Black or African American; Brain Diseases, Metabolic; Carnitine; Cogn | 2010 |
Hematological effects of valproate in psychiatric patients: what are the risk factors?
Topics: Adolescent; Adult; Aged; Anemia, Macrocytic; Blood Cell Count; Cross-Sectional Studies; Female; Hema | 2010 |
Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients.
Topics: Adult; Aged; Antimanic Agents; Carnitine; Female; Humans; Inpatients; Male; Mental Disorders; Middle | 2011 |
Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units.
Topics: Aged; Alzheimer Disease; Androgen Antagonists; Antipsychotic Agents; Cholinesterase Inhibitors; Cypr | 2011 |
The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data.
Topics: Adolescent; Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; F | 2011 |
Novel evidence of the involvement of calreticulin in major psychiatric disorders.
Topics: Antimanic Agents; Calreticulin; Case-Control Studies; Cell Line; Cells, Cultured; Female; Gene Expre | 2012 |
Valproic acid treatment is associated with altered leukocyte subset development.
Topics: Eosinophils; Hematopoiesis; Humans; Leukocyte Count; Leukocytes; Lymphocyte Subsets; Mental Disorder | 2012 |
Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Topics: Adolescent; Adult; Aged; Child, Preschool; China; Epilepsy; Female; Humans; Hyperammonemia; Male; Me | 2013 |
The safety of valproic acid use for patients with hepatitis C infection.
Topics: Adult; Alanine Transaminase; Chemical and Drug Induced Liver Injury; Female; Follow-Up Studies; Hepa | 2003 |
Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity.
Topics: Alcoholism; Animals; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Humans; Mental | 2004 |
Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.
Topics: Adolescent; Adult; Age Factors; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Dibenzothia | 2004 |
Valproic acid intoxication: sense and non-sense of haemodialysis.
Topics: Adult; Drug Overdose; Epilepsy; Ethanol; Hemodiafiltration; Hemoperfusion; Humans; Male; Mental Diso | 2004 |
Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study.
Topics: Adult; Aged; Amylases; Anticonvulsants; Carnitine; Cross-Sectional Studies; Female; Humans; Liver Fu | 2005 |
Fit for a fracture.
Topics: Anticonvulsants; Epilepsy; Ergocalciferols; Female; Femoral Neck Fractures; Follow-Up Studies; Fract | 2005 |
Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Cross-Sectional Studies; Depressive Disorder; Female | 2006 |
Epilepsy with myoclonic absences.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsy, Tonic-Clonic; F | 2006 |
Anticonvulsant treatment for psychiatric and seizure indications among youths.
Topics: Adolescent; Age Factors; Ambulatory Care; Anticonvulsants; Child; Child, Preschool; Community Mental | 2006 |
The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children.
Topics: Anticonvulsants; Carbamazepine; Child; Cognition; Education, Special; Epilepsy; Female; Humans; Ment | 2006 |
Juvenile myoclonic epilepsy: a benign disorder? Personality traits and psychiatric symptoms.
Topics: Adolescent; Adult; Anticonvulsants; Child; Ethosuximide; Female; Fructose; Humans; Lamotrigine; Leve | 2007 |
Adherence to pharmacological treatment for juvenile bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Child; Child of Impaired Parents; Female; Humans; Lithium Carbon | 2007 |
Intravenous valproate treatment of uncontrollable aggression: a case report.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationshi | 2007 |
Lamotrigine serum concentrations under valproate comedication: "contraindication" or "safe combination"? A case report.
Topics: Adult; Anticonvulsants; Antimanic Agents; Chromatography, High Pressure Liquid; Contraindications; D | 2007 |
Psychiatric implications of anticonvulsant drugs.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Dose-Response Relationship, Dr | 1980 |
Pharmacodynamic factors in the occurrence of psychiatric symptoms among patients with epilepsy.
Topics: Anticonvulsants; Barbiturates; Carbamazepine; Epilepsy; Folic Acid; Humans; Kinetics; Mental Disorde | 1983 |
Adverse effects of valproate.
Topics: Gastrointestinal Diseases; Hematologic Diseases; Humans; Mental Disorders; Metabolic Diseases; Nervo | 1984 |
[Stupor due to sodium valproate. Immediate arousal after intravenous diazepam (author's transl)].
Topics: Child; Diazepam; Electroencephalography; Humans; Injections, Intravenous; Male; Mental Disorders; Va | 1981 |
Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Tolerance; Female; H | 1995 |
Treating the agitated Alzheimer patient.
Topics: Adrenergic beta-Antagonists; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Buspirone; C | 1996 |
Drugs for psychiatric disorders.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Benzodi | 1997 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Administration Sche | 1997 |
Pathological laughter following intravenous sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Humans; Injections, Intravenous; Laughter; Male; Mental Disorder | 1998 |
The naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; | 1998 |
Clinical correlates of response to valproate in geriatric inpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Drug Administration Schedu | 1998 |
Introduction: the use of mood stabilizers in the treatment of psychiatric disorders.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; Li | 1999 |
The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hospitalization; Hu | 1999 |
Valproate-induced hyperammonemia in the psychiatric setting: 2 cases.
Topics: Adult; Ammonia; Anticonvulsants; Bipolar Disorder; Humans; Male; Mental Disorders; Middle Aged; Psyc | 1999 |
Gastrointestinal adverse effects with divalproex sodium and valproic acid.
Topics: Dose-Response Relationship, Drug; Gastrointestinal Diseases; Hospitalization; Humans; Incidence; Men | 2000 |
Occurrence of thrombocytopenia in psychiatric patients taking valproate.
Topics: Age Factors; Aged; Anticonvulsants; Drug Monitoring; Female; Hospitalization; Humans; Male; Mental D | 2001 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Pediatric migraine prophylaxis with divalproex.
Topics: Adolescent; Child; Epilepsy, Generalized; Epilepsy, Rolandic; Female; Humans; Male; Mental Disorders | 2001 |
Retrospective evaluation of the effect of valproate therapy on transaminase elevations in patients with hepatitis C.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chi-Squar | 2001 |
[Tardive dyskinesia. Synthetic-critical review and case contribution].
Topics: Adult; Aged; Baclofen; Dyskinesia, Drug-Induced; Female; Humans; Iatrogenic Disease; Male; Mental Di | 1977 |
[Acupunctura, "vital" drugs and psychopharmacological agents in the treatment of psychiatric patients with deep depressive disorders, with considerations on the probable neurophysiological mechanisms of the synergism of action].
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Female; Glutamine; Humans; Male; Mental Disorders; Mid | 1977 |
[Acupuncture, "vital" drugs and psychotropic agents in psychiatric patients. 50 cases].
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Drug Evaluation; Evaluation Studies as Topic; Female; | 1978 |
[Clinical study of the normothymic effect of dipropylacetamide].
Topics: Adolescent; Adult; Drug Evaluation; Female; Humans; Lithium; Male; Mental Disorders; Middle Aged; Ps | 1976 |
Valproate as psychotropic agent. Interactions and adverse cerebral reactions.
Topics: Adult; Antipsychotic Agents; Consciousness; Drug Interactions; Electroencephalography; Humans; Male; | 1985 |
[Various matters concerning the improvement of therapeutic tactics in epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Drug Therapy, Comb | 1986 |
Sodium valproate: its use in primary psychiatric disorders.
Topics: Adolescent; Adult; Electroencephalography; Humans; Mental Disorders; Valproic Acid | 1987 |